21 Ha’arba’a Street
367 articles with RedHill Biopharma
RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib
Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthen s manufacturing capabilities and capacity , in preparation for potential emergency use applications -- Enrollment in the g lobal Phase 2/3 COVID-19 study with opaganib is advancing rapidly following approval s in 6 countries -- U.S . Phase 2 COVID-19 study with opaganib
10/8/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19 -- The U.S. Phase 2 study is 75% enrolled with data expected later this quarter -- In parallel, e nrollment advancing rapidly in the g lobal COVID-19 P hase 2/3 study with opaganib -- Global emergency use authorization applications are planned, subject t
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will present at the following virtual conferences in October:
9/24/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data
Veeva Vault CDMS and Bioforum selected to optimize clinical data management for RedHill’s global Phase 2/3 clinical trial evaluating opaganib in patients with severe COVID-19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing global Phase 2/3 study evaluating opaganib1 in patients hospitalized with severe COVID-19 pneumonia.
9/10/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
RedHill to Present at the Morgan Stanley Annual Global Healthcare Conference and Additional September Events
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that RedHill’s Chief Executive Officer, Dror Ben-Asher, will present at the Morgan Stanley Annual Global Healthcare Conference, on Thursday, September 17, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive control in the study -- Opaganib is uniquely positioned as an orally-administered potential COVID-19 treatment combining potent antiviral and anti-inflammatory mechanisms of actio n, targeting a host cell component and minimizing likelihood of resistance -- Global Phase 2/3 and U.S. Phase 2
A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia, and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with dual anti-inflammatory and anti-viral properties
RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
A pre-scheduled independent Safety Monitoring Committee (SMC) has recommended that the U.S. Phase 2 COVID-19 study with opaganib continue with no changes; the study is more than 50% enrolled and enrollment is planned to be completed in the coming weeks
Q2/2020 net revenues of approximately $21 million, up from $1.1 million in Q1/2020 and $1.6 million in Q2/2019, an increase of approximately 1,900% and 1,200%, respectively
RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. for an exclusive licensing and manufacturing agreement for multiple products.
The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe COVID-19 across 40 clinical sites
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will participate in the following virtual conferences in August
RedHill acquired Movantik® for opioid induced constipation from AstraZeneca in April 2020; Movantik® generated $96 million in 2019
RHB-204 is a potential first-line oral treatment for pulmonary nontuberculous mycobacteria (NTM) infections, a rare disease with no FDA-approved first-line therapy